Page 5 - Junshi Bioscience News Today

Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting - read this article along with other careers information, tips and advice on BioSpace

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting

-- Preliminary study results show that tifcemalimab is well-tolerated at all administered doses. The observed clinical activity of tifcemalimab in...

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Submission of a Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency

-- 2nd MAA submission in Europe reflects toripalimab's steady yet speedy progress towards global commercializationSHANGHAI, China, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection

SHANGHAI, China, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading...

SHANGHAI, China, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated

--The MAA was submitted in the EU for toripalimab seeking indications for the 1st line treatment of NPC and the 1st line treatment of ESCC -- The global commercialization plan for toripalimab

Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Submission of a Marketing Authorization Application to the European Medicines Agency for Toripalimab